Robert Croop

2.9k total citations · 4 hit papers
106 papers, 2.0k citations indexed

About

Robert Croop is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Sensory Systems. According to data from OpenAlex, Robert Croop has authored 106 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Psychiatry and Mental health, 19 papers in Pathology and Forensic Medicine and 19 papers in Sensory Systems. Recurrent topics in Robert Croop's work include Migraine and Headache Studies (82 papers), Olfactory and Sensory Function Studies (19 papers) and Trigeminal Neuralgia and Treatments (16 papers). Robert Croop is often cited by papers focused on Migraine and Headache Studies (82 papers), Olfactory and Sensory Function Studies (19 papers) and Trigeminal Neuralgia and Treatments (16 papers). Robert Croop collaborates with scholars based in United States, United Kingdom and Germany. Robert Croop's co-authors include Vladimir Coric, Richard B. Lipton, Charles M. Conway, David Stock, Peter J. Goadsby, Elyse Stock, Micaela Forshaw, David Kudrow, Alexandra Thiry and Beth Morris and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Robert Croop

95 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

2019 276 citations Robert Croop, David Stock et al. profile →
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

2019 265 citations Richard B. Lipton, Robert Croop et al. profile →
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

2020 233 citations Robert Croop, Richard B. Lipton et al. profile →
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

2023 85 citations Richard B. Lipton, Robert Croop et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert Croop	1.4k	858	594	243	221	106	2.0k
Christopher Assaid	1.0k 0.7×	621 0.7×	615 1.0×	66 0.3×	195 0.9×	21	1.8k
TJ Steiner	2.6k 1.9×	1.4k 1.7×	984 1.7×	116 0.5×	152 0.7×	65	3.2k
Christian Lampl	2.4k 1.7×	1.4k 1.6×	857 1.4×	82 0.3×	94 0.4×	69	3.0k
Neil H. Raskin	1.3k 0.9×	940 1.1×	689 1.2×	175 0.7×	244 1.1×	51	2.4k
Andrea Negro	1.9k 1.4×	1.1k 1.3×	691 1.2×	33 0.1×	89 0.4×	78	2.3k
Grethe Helde	1.4k 1.0×	474 0.6×	347 0.6×	55 0.2×	111 0.5×	46	1.9k
Mahnaz Asgharnejad	894 0.6×	393 0.5×	398 0.7×	76 0.3×	159 0.7×	63	1.6k
Robert P. Cowan	1.0k 0.7×	504 0.6×	358 0.6×	41 0.2×	80 0.4×	68	1.5k
Jessica Ailani	2.9k 2.0×	1.8k 2.1×	1.0k 1.8×	44 0.2×	103 0.5×	120	3.3k
Fred D. Sheftell	2.8k 2.0×	1.7k 2.0×	1.2k 2.1×	43 0.2×	65 0.3×	99	3.2k

Countries citing papers authored by Robert Croop

Since Specialization

Citations

This map shows the geographic impact of Robert Croop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Croop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Croop more than expected).

Fields of papers citing papers by Robert Croop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Croop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Croop. The network helps show where Robert Croop may publish in the future.

Co-authorship network of co-authors of Robert Croop

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Croop. A scholar is included among the top collaborators of Robert Croop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Croop. Robert Croop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ikeda, Koichi, Yasuhiko Matsumori, Masako Kudo, et al.. (2025). Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial. Headache The Journal of Head and Face Pain. 65(10). 1811–1820. 2 indexed citations

Matsumori, Yasuhiko, Tomofumi Ishikawa, Hiroki‎ Yoshimatsu, et al.. (2025). Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial. Headache The Journal of Head and Face Pain. 65(8). 1403–1412. 3 indexed citations

Matsumori, Yasuhiko, Tomofumi Ishikawa, Hiroki‎ Yoshimatsu, et al.. (2025). Plain Language Summary Publication: Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial. Headache The Journal of Head and Face Pain.

Lipton, Richard B., et al.. (2024). Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Pain Research. Volume 17. 2431–2441. 14 indexed citations

Mullin, Kathleen, et al.. (2024). Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study. Cephalalgia. 44(8). 2225304512–2225304512. 5 indexed citations

Croop, Robert, Gary Berman, David Kudrow, et al.. (2024). A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 44(4). 2225278000–2225278000. 22 indexed citations

Bhardwaj, Rajinder, Jennifer Madonia, Beth Morris, et al.. (2024). Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment. Clinical and Translational Science. 17(7). e13813–e13813. 4 indexed citations

Bhardwaj, Rajinder, et al.. (2024). No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults. Clinical and Translational Science. 17(3). e13727–e13727. 3 indexed citations

Bhardwaj, Rajinder, Jennifer Madonia, Matt S. Anderson, et al.. (2024). Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects. Clinical and Translational Science. 17(10). e70015–e70015. 4 indexed citations

10.

Bhardwaj, Rajinder, Jennifer Madonia, Matt S. Anderson, et al.. (2024). Deconvoluting zavegepant drug–drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics. Clinical and Translational Science. 17(12). e70048–e70048. 1 indexed citations

11.

Bhardwaj, Rajinder, et al.. (2023). The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Study. Clinical Pharmacology in Drug Development. 13(1). 37–44. 3 indexed citations

12.

Croop, Robert, Thomas Shiovitz, Arifulla Khan, et al.. (2022). An Open-label, Intermediate-sized, Expanded Access Protocol of Rimegepant in the Acute Treatment of Migraine (P2-2.006). Neurology. 98(18_supplement). 1 indexed citations

13.

L’Italien, Gilbert, Evan Popoff, Linda Harris, et al.. (2021). Acute Treatment with Rimegepant 75 mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days – Post Hoc Results from an Open Label Safety Study (BHVN-3000-201) (4737). Neurology. 96(15_supplement). 1 indexed citations

14.

Turner, Ira, Paul Winner, Richard B. Lipton, et al.. (2021). Acute Treatment of Migraine with Rimegepant Improves Health Related Quality of Life in Adults With a History of Triptan Treatment Failure: Results from a Long-Term, Open-Label Safety Study (5029). Neurology. 96(15_supplement). 1 indexed citations

15.

Schim, Jack, Susan Hutchinson, Richard B. Lipton, et al.. (2021). Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study (2370). Neurology. 96(15_supplement). 4 indexed citations

16.

McAllister, Peter, Gary Berman, David Kudrow, et al.. (2020). Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402). Neurology. 94(15_supplement). 1 indexed citations

17.

Croop, Robert, Richard B. Lipton, Elyse Stock, et al.. (2020). Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112). Neurology. 94(15_supplement).

18.

Pavlović, Jelena, David W. Dodick, Lawrence C. Newman, et al.. (2020). Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091). Neurology. 94(15_supplement). 1 indexed citations

19.

Conway, Charles M., Robert Croop, Gene M. Dubowchik, Vladimir Coric, & Richard B. Lipton. (2020). Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays (2141). Neurology. 94(15_supplement). 12 indexed citations

20.

Hanna, Michael, et al.. (2020). Rimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects (2117). Neurology. 94(15_supplement). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact